Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 714 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07563595Recruiting
Elacestrant for advanced ER+ HER2- breast cancer with ESR1 mutation
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
Freiburg im BreisgauAges 18 years+ - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT07556562Recruiting
Early ovarian cancer detection through Pap test DNA analysis
This study tests whether DNA found in routine Pap smears can help detect ovarian cancer early in people at high genetic risk. Participants have inherited gene mutations that increase ovarian cancer risk and are considering preventive surgery.
Roma, RomaAges 18 years+ - NCT07547163Recruiting
Patient feedback on low-grade brain tumor treatment
This study asks patients with a specific type of low-grade brain tumor (IDH mutant grade 2 glioma) to share their experiences and quality of life while receiving a treatment called vorasidenib, with or without radiation. Your feedback helps doctors understand how well the treatment works from your perspective.
MilanAges 18 years+ - NCT07548060RecruitingPhase 2
New drug combination for advanced lung cancer after prior treatments
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07538804RecruitingPhase 1/Phase 2
Testing ANS02 for EGFR-Mutated Lung Cancer
This trial tests a new drug called ANS02 in people with non-small cell lung cancer (a common type of lung cancer) that has a specific genetic change called an EGFR mutation. The drug is designed to target and slow cancer growth in people with this mutation.
Fairfax, VirginiaAges 18 years+ - NCT07535112RecruitingPhase 1
Study of a new drug for advanced colorectal cancer with KRAS G12D mutation
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT06749015Recruiting
Study for BRAFV600E Mutant Metastatic Colorectal Cancer
This trial tests a treatment for people whose colorectal cancer has spread and cannot be removed by surgery, and who have a specific gene change called BRAFV600E. It aims to find out if the treatment can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06653127Recruiting
Using a blood test to watch for biliary tract cancer return
This trial studies a new blood test that looks for bits of tumor DNA (ct-mtDNA) to see if it can detect if biliary tract cancer has come back earlier than standard scans. The test might help doctors monitor for recurrence more closely.
Wuhan, HubeiAges 18 years+ - NCT06653062Recruiting
Blood test to watch for liver cancer return
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
Wuhan, HubeiAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Birmingham, AlabamaAges 18 years+ - NCT07518160RecruitingPhase 2
JS212 and JS111 for advanced lung cancer with EGFR mutations
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06755684RecruitingPhase 2
Pre-surgery targeted drug combo for EGFR-mutant lung cancer
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07507760RecruitingPhase 2
Oral decitabine plus ivosidenib for older AML patients
This trial tests a combination of two oral drugs (decitabine and ivosidenib) as a first treatment for older or frail adults with AML that has an IDH1 mutation. The goal is to see if this pill-only regimen is safe and effective without needing intensive chemotherapy.
AveiroAges 18 years+ - NCT06556394RecruitingPhase 1
Testing RAG-17 for ALS with SOD1 gene mutation
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
BeijingAges 18 years+ - NCT07498829Recruiting
Cancer risk genetic testing for people with female organs
This study offers free genetic testing to women, trans men, and non-binary people (with female reproductive organs) who have not had previous testing for certain cancer-related genes. It aims to find people at higher risk for cancer so they can take steps to prevent it or catch it early.
LondonAges 18 years+ - NCT07506109RecruitingPhase 2
Study of sintilimab, ipilimumab, cetuximab, and dabrafenib for advanced colorectal cancer
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07499271RecruitingPhase 2
Targeted therapy for newly diagnosed DLBCL with TP53 mutation
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
Suzhou, JiangsuAges 18–70 - NCT07493096Recruiting
Intensive therapy program for children with brain-based conditions
This trial tests an intensive therapy program designed to help children with brain-based conditions like cerebral palsy or autism improve their skills in movement, thinking, and daily activities. The program runs for 2 weeks with daily sessions, and researchers will check for changes in your child's abilities.
The Woodlands, TexasAges 4–12 - NCT07492342RecruitingPhase 2
Fulzerasib with immunotherapy and chemo before surgery for KRAS G12C lung cancer
This trial tests a combination of a targeted pill (Fulzerasib) and immunotherapy (Sintilimab) plus standard chemotherapy before surgery, for people with early-stage non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to shrink the tumor and make surgery more effective.
BeijingAges 18 years+ - NCT07486817RecruitingPhase 2
Testing zongertinib with chemo and immunotherapy for advanced lung cancer
This trial tests a new drug called zongertinib combined with chemotherapy, with or without pembrolizumab (an immunotherapy), for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The goal is to see how safe and well-tolerated the combination is.
St Leonards, New South WalesAges 18 years+ - NCT07486713RecruitingPhase 4
Olutasidenib drug interaction study for IDH1 mutation cancers
This trial tests how olutasidenib interacts with other drugs in people with cancers that have an IDH1 mutation, like certain leukemias or brain tumors. Participation may help determine the best way to take this treatment safely.
Orange, CaliforniaAges 18 years+ - NCT06779864Recruiting
Hepatitis B virus genetics and drug resistance study
This study looks at how hepatitis B virus changes in your body, including mutations and drug resistance, using your blood or liver tissue samples. Understanding these changes could help improve treatment for hepatitis B.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07472686Recruiting
Capsule endoscopy for small bowel in Lynch syndrome
This study looks at how well a tiny camera in a pill (capsule endoscopy) can find early growths or cancer in the small intestine of people with Lynch syndrome. Lynch syndrome increases your risk for certain cancers, and this test might help catch them earlier.
ParisAges 18 years+
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 714 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.